Arrowhead Pharmaceuticals shares rose after the company said it saw positive topline results for its global Phase 3 clinical studies of plozasiran in patients with severe hypertriglyceridemia, a condition that significantly increases the risk of acute pancreatitis.

Shares of Arrow were 21% higher, at $90.50 on Wednesday after hitting their 52-week high of $95.49 earlier in the session.

The company said the two studies successfully met the primary endpoint of triglyceride reduction versus placebo and met all prespecified secondary endpoints, including a statistically significant reduction in the rate of acute pancreatitis compared to placebo.

Plozasiran demonstrated a favorable safety and tolerability profile in the studies, with overall treatment emergent adverse events and related TEAEs consistent with its established safety profile from prior studies. There were no clinically meaningful differences in routine clinical laboratory measurements, and no new safety signals.

Plozasiran has received regulatory approval, as Redemplo, in the U.S., the European Union, China, Australia and Canada as an adjunct to diet to reduce triglycerides in adults with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome, which is the most severe form of sHTG.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 22, 2026 13:20 ET (17:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.